



CANADIAN APHERESIS GROUP
GROUPE CANADIEN D'APHÉRÈSE

SPONSORSHIP OPPORTUNITIES

**Annual General Meeting
and Exhibit**

**Education and
Development Initiatives**



2023

WHO WE ARE



CANADIAN APHERESIS GROUP
GROUPE CANADIEN D'APHÉRÈSE

FORMATION AND MEMBERSHIP

The Canadian Apheresis Group (CAG) was formed in 1980 under the auspices of National Health and Welfare, Canada. Our members represent all (more than 42) apheresis units performing therapeutic apheresis in major medical centres across Canada.

MISSION AND VISION

The CAG aids in the assessment and application of new and innovative apheresis techniques and provides education and advice to Canadian practitioners to ensure that therapeutic apheresis is applied in a humane and scientifically sound manner across the country, with optimal cost-efficiency and preservation of our national blood supply.

INTERNATIONAL LEADERSHIP AND COLLABORATION

In 1986, the CAG, together with seven other professional apheresis societies, established the World Apheresis Association (WAA). The WAA now represents 19 member societies around the globe and is still growing. It serves as an umbrella organization for national and international professional societies devoted to all aspects of apheresis. The CAG remains an active and dynamic participant of the WAA.

As a national organization, the CAG fosters relationships and liaises with other national and international apheresis societies. We promote the study of apheresis by encouraging cooperative clinical trials across Canada and in association with international bodies, and we foster basic research into the mechanisms of the diseases treated.

CLINICAL TRIALS, STUDIES AND PUBLICATIONS

Since its inception, the CAG has undertaken the organization and direction of many randomized controlled studies of plasma exchange and pharmaceutical products.

As pharmaceuticals are increasingly used to enhance therapeutic apheresis and to augment therapy, we constantly evaluate various drugs to assist our member-physicians to provide optimal therapy. Our many clinical trials over the years have been instrumental in defining therapy and introducing new approaches to patient care in Canada and around the world.

Our collaborative studies have resulted in the publications of 15 papers on TTP alone and a total of 44 papers on various aspects of apheresis.

CAG NATIONAL APHERESIS REGISTRY

Decades ago, the CAG created a National Apheresis Registry database to collect information on all apheresis procedures in Canada and to monitor the effectiveness of treatment and to survey associated complications. We have expanded and improved our national registry over the years through the review, analysis and feedback from apheresis doctors and nurses across the country and by modernizing it to increase data-capture, reduce input errors, monitor adverse events in real-time and to lessen the burden on users by taking advantage of new and emerging technologies as they become available.

We collect data on plasma exchange, cytappheresis (including stem cell and lymphocyte collections), photopheresis and column apheresis procedures across Canada. Each year CAG members do over 10,000 plasma exchange procedures using plasma, albumin and crystalloids as the replacement fluids. As such, we use more than 10% of all of the plasma collected in the country.

For more information, visit www.cagcanada.ca

“Our many clinical trials over the years have been instrumental in defining therapy and introducing new approaches to patient care in Canada and around the world.”

SPONSORSHIP OPPORTUNITIES

As the only association for apheresis physicians in Canada, we provide a unique opportunity for industry partners and not-for-profit organizations to collaborate in research, education and networking.

MAJOR OPPORTUNITIES TO SUPPORT ARE :

- **ANNUAL GENERAL MEETING**
- **THE CAG REGISTRY**
- **EDUCATIONAL AND DEVELOPMENT PROGRAMS**

The CAG is requesting an unrestricted educational grant to support our activities. This is exclusive of our other costs such as the AGM and clinical trials.

As an organization with a long-standing prominence on the national stage, the CAG invites you to sponsor our Education and Development initiatives and to participate in our Annual General Meeting.

EDUCATION AND DEVELOPMENT

The CAG created and maintains a National Registry through which data is collected on all apheresis procedures across the country. Through this data we monitor outcomes of the procedures and plan practice improvements.

We also track the incidence of blood-borne pathogens in specialized population groups. The statistics are collected annually and are shared, reviewed and discussed at our annual general meeting.

Our National Registry is a web-based system that allows us to track reactions in real time. Our data provide vital information on the diseases treated in each centre, the fluids used and the types of reactions seen. Outcome data is also collected.

Funding is needed to maintain the registry and to facilitate communication among the apheresis centres about essential matters including protocol development, national data collection and education.

The CAG operations budget covers the development of educational programs and the necessary orientation and training of both nurses and physicians for the National Registry.

ANNUAL GENERAL MEETING

The CAG's Annual General Meeting (AGM) is the premier event for Canada's apheresis physicians and nurses—the leaders in this field from across Canada.

This is your opportunity to display your product to a captive audience. Our sponsors will receive recognition to position the corporate brand clearly to the delegates.

At this event, our physicians and nurses come together to discuss and review our progress and to share ideas that relate to this field of practice and to plan future projects. The Corporate Exhibit component of our AGM is a valuable opportunity to showcase products to Canada's leading apheresis physicians and nurses, each representing their local or regional centre.

The AGM focuses on new apheresis evidence and techniques. We also carry out a centre-by-centre activities review; physicians from each medical centre explain variances in their centres' activity, with reference to available published evidence. Based on these discussions and on the national data, the feasibility of future pilot or randomized controlled studies are also discussed at our AGM.

Adverse events, fluids use and other key topics are reported and discussed at the AGM. National and international expert guest speakers address new or improved approaches to practice.

SPONSORSHIP LEVELS

DEFINITION OF LEVELS	Platinum \$50,000.00	Gold \$30,000.00	Silver \$20,000.00	Bronze \$15,000.00
Named as Sponsor for your level on the CAG Website	✓	✓	✓	✓
Complimentary, full registration for the CAG AGM	6	4	3	2
Provide suggestions for topics /speakers at AGM	✓	✓	✓	✓
Exhibit: complimentary table-top booth	1	1	1	1
Corporate recognition on the CAG website (in sponsors list)	✓	✓	✓	✓
Corporate recognition at the CAG AGM	✓	✓	✓	✓
Recognition in the CAG AGM Meeting Book	✓	✓	✓	✓

EXHIBIT OPPORTUNITIES AT THE CAG ANNUAL GENERAL MEETING

The CAG exhibit aspect of our annual meeting offers your best opportunity to introduce yourself and your products to the physicians and nurses who deal with apheresis every day and for whom this is a must-attend event.

PLAN TO JOIN US IN 2023 !

For more information Contact: **Nathalie Brun**

Phone: **613-748-9613**

Email: **cag@cagcanada.ca**

Fax: **613-748-6392**